☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Rheumatoid Arthritis
Fresenius Kabi Reports Results of MSB11456 (biosimilar- tocilizumab) in Two Clinical Trials for the Treatment of Rheumatoid Arthri...
September 7, 2021
Celltrion Launches Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis in Canada
June 7, 2021
Celltrion Presents One Year Results of Yuflyma (biosimilar- adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULA...
June 3, 2021
Biogen and Bio-Thera Report Results of BAT1806 (biosimilar- tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthriti...
June 3, 2021
AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheu...
June 2, 2021
Biogen Signs a License and Commercialization Agreement with Bio-Thera for BAT1806 (biosimilar- tocilizumab) to Treat Moderate to S...
April 9, 2021
Alvotech and Teva’s Simlandi (Biosimilar, Humira) Receives the US FDA’s Approval for the Treatment of Multiple Indications
February 26, 2024
SynAct Pharma Reports Additional Results of the P-IIb (EXPAND) Study Supporting the Development of Resomelagonin for Rheumatoid Ar...
February 22, 2024
Celltrion Reports BLA Submission for CT-P47 (Biosimilar, Actemra) to the US FDA for Treating Rheumatoid Arthritis
January 29, 2024
Shorla Oncology Reports the Acquisition of Jylamvo from Therakind Targeting Oncology and Autoimmune Indications
November 1, 2023
Menarini Entered into an Exclusive License Agreement with Astellas to Commercialize Smyraf in Taiwan and Selected South-East Asian...
September 13, 2023
Shanghai Biomabs Pharmaceutical Reports P-III Study Results of CMAB008 (biosimilar, infliximab) for Rheumatoid Arthritis
August 14, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.